Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05364957
Other study ID # RC31/18/0473
Secondary ID 2019-A00595-52
Status Recruiting
Phase N/A
First received
Last updated
Start date May 12, 2023
Est. completion date August 2026

Study information

Verified date June 2023
Source University Hospital, Toulouse
Contact Guilleminault Laurent, MD
Phone 05 67 77 18 50
Email guilleminault.l@chu-toulouse.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this project is to study the effect of an intragastric balloon (IGB) on asthma control in obese patients. Obese patients with uncontrolled asthma will be recruited and randomly assigned to two intervention arms : an intragastric balloon combined with diet and exercise versus diet and exercise alone (control group). The primary endpoint will be the proportion of patients with an improvement based on an Asthma Control Questionnaire (ACQ) score ≥ 0.5 at 1 year compared to baseline.


Description:

Asthma and obesity are two major public health problems worldwide. It is now well established that there is a strong link between obesity and asthma. Management of obese patients with asthma is complex in clinical practice because, compared to asthma patients with a normal weight, obese patients with asthma are more prone to respiratory symptoms, asthma attacks and hospital admissions. Lower sensitivity to asthma treatments has also been observed. Indeed, obese patients with moderate to severe asthma respond less well to inhaled corticosteroids, which constitute the recommended treatment for asthma. Improved therapeutic strategies are required for obese patients with uncontrolled asthma.


Recruitment information / eligibility

Status Recruiting
Enrollment 84
Est. completion date August 2026
Est. primary completion date July 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Men and women aged between 18 and 65 years 2. Asthma according to the Global Initiative for Asthma (GINA) criteria 3. Patients with uncontrolled asthma based on an ACQ score =1.5 despite inhaled corticosteroids ± long acting bronchodilators (LABA) 4. Patients with grade I obesity (BMI> 30 kg/m² and < 35 kg/m²) or morbid obesity (BMI<40 or =35 kg/m² with serious physiological risks, as recommended by the French Health Authorities) with contraindications for or refusal of bariatric surgery. 5. Effective contraception for women 6. Patients who have signed a written informed consent form 7. Patients with health insurance 8. Complete COVID-19 vaccination schedule according to current guidelines Exclusion Criteria: 1. Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) 2. Blood eosinophilia greater than 4.5 G/I 3. Treatment by biotherapy within the 12 months after inclusion 4. Cancer diagnosed within the last 5 years 5. Smoking > 10 packs/year (PA) 6. One asthma exacerbation in the 4 weeks leading up to the inclusion visit or IGB placement. 7. Treatment with orlistat Xénical® or GLP1 analogues or regular consumption of narcotics (heroin, cocaine and amphetamines). Analgesic treatments, including level 3, are authorized during the study. 8. Any patient for whom IGB is contraindicated [criteria defined by the French Society for Digestive Endoscopy) and the French Think-Tank for Hepato-Gastroenterology Practices]: 8.1 Severe cognitive or psychiatric disorders, chronic alcoholism, drug addiction 8.2 Severe and unstabilised eating disorders: bulimia or history of anorexia 8.3 History of gastric surgery including the ring insertion 8.4 Haemostasis disorders 8.5 Anticoagulant or non-steroidal anti-inflammatory medicines 8.6 Severe liver disease 8.7 Pregnancy or desire to become pregnant or breastfeeding 8.8 Anticipated failure to comply with prolonged medical follow-up 8.9 Large hiatal hernias > 5 cm, inflammatory (Crohn's) or stenosing small bowel disease, pyloric stenosis and structural abnormalities of the digestive tract 8.10 Systemic lupus erythematous 8.11 Severe oesophagitis and active gastroduodenal ulcer 8.12 Silicone allergy 9. Patient under guardianship or tutorship, persons placed under the protection of justice or persons participating in another search including an exclusion period still in progress

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Intragastric balloon device
Patients in the experimental arm will benefit from the placement of an Intra Gastric Balloon endoscopically
Procedure:
Dietary
The patient will benefit from dietary intervention that follows a standard medical recommendation; In consultation with a dietician (at M1, M4, M7, M13, M19, M25), patients will be asked to follow an appropriate diet with a balanced intake of macronutrients (55% carbohydrates, 30% lipids and 15% proteins).
Exercise intervention
Patient will benefit from exercise intervention; Resistance and aerobic exercises will be performed twice a week for 3 months (between M4 and M7) under the supervision of a physiotherapist.

Locations

Country Name City State
France University Hospital Toulouse Toulouse Occitanie

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Toulouse

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Other Physical activity The change of physical activity score measured by the Ricci and Gagnon Questionnaire compared to baseline. The total score is divided into 3 categories:
under 18 means inactive physical activity; between 18 and 35 means active physical activity; over 35 means very active activity
6 months, 12 months, 18 months and 24 months
Other Immunoglobulin E (IgE) repertoire of B-lymphocytes The change of the IgE repertoire of B-lymphocytes compared to baseline: through the gene expression signature profiling of specific IgEs of Der p 1 and Der p 2 (the two main allergens of mites) produced by B cells, using a single cell RNA sequencing technique. 12 months
Primary Asthma Control Survey the proportion of patients with changed asthma control at 12 months , defined as a reduction in the Asthma Control Score (ACQ) = 0.5, compared to baseline. 12 months
Secondary Asthma control The proportion of patients with changed asthma control at 6 months, 18 months and 24 months, defined as a reduction in the asthma control score (ACQ) = 0.5 compared to baseline. 6 months, 18 months and 24 months
Secondary Weight loss Weight loss evaluated according to the percentage weight loss from baseline to post-procedure ([weight before (in kg) - weight after (in kg)] / weight before (in kg)). 6 months, 12 months, 18 months and 24 months
Secondary The number of patients with an Asthma Control Questionnaire score = 1 The proportion of patients with an Asthma Control Questionnaire score = 1 measured by ACQ questionnaire 6 months, 12 months, 18 months and 24 months
Secondary The change of exacerbations The change of exacerbations which is defined as a course of oral corticosteroids compared to the 12 months period before intervention 6 months, 12 months, 18 months and 24 months
Secondary The change of hospital admissions or emergency visits for asthma exacerbation The change in the annual number of hospital admissions or emergency visits for asthma exacerbation compared to baseline with data collection by questionnaire. 6 months, 12 months, 18 months and 24 months
Secondary Inhaled corticosteroids daily dose The change of inhaled corticosteroids daily dose (in ug/d) compared to baseline 6 months, 12 months, 18 months, 24 months.
Secondary Forced expiratory volume in 1 second The change of forced expiratory volume in 1 second (FEV 1) value measured by plethysmography, and fractions of exhaled nitric oxide (FENO) compared to baseline. 6 months, 12 months, 18 months and 24 months
Secondary vital capacity The change of vital capacity value measured by plethysmography, and fractions of exhaled nitric oxide (FENO) compared to baseline. 6 months, 12 months, 18 months and 24 months
Secondary Total lung capacity the change of total lung capacity value measured by plethysmography, and fractions of exhaled nitric oxide (FENO) compared to baseline. 6 months, 12 months, 18 months and 24 months
Secondary Asthma quality The change of mini-Asthma Quality of Life Questionnaire score compared to baseline.The score is evaluated on 7 points, the highest score indicates a better quality of life 6 months, 12 months, 18 months and 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2